Actinium Pharmaceuticals to Present at the Biotech Showcase™ 2013

      Actinium Pharmaceuticals to Present at the Biotech Showcase™ 2013

Actinium Pharmaceuticals will present clinical progress of its lead drug
candidates to investors and biotech industry executives for the first time as
a public company

PR Newswire

NEW YORK, Jan. 4, 2013

NEW YORK, Jan. 4, 2013 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (OTCBB:
CTVN) today announced that Jack Talley, the company's President and Chief
Executive Officer, will be presenting at the Biotech Showcase in San Francisco
on Monday, January 7, 2013 at 11:45 AM Pacific Time.

The presentation will include an overview of Actinium's clinical stage drug
candidates Actimab-A and Iomab-B for treatment of hematological cancers and
discussion of its proprietary patented alpha particle immunotherapy technology

The Biotech Showcase is being held at the Parc 55 Wyndham Union Square Hotel
in San Francisco and it provides private and publiclife sciencecompanies the
opportunity to present to an audience of investors and business development

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical
company that develops innovative alpha particle immunotherapeutics based on
its proprietary platform for the therapeutic utilization of alpha particle
emitting actinium-225 and bismuth-213 isotopes in association with monoclonal
antibodies. The Company also develops other radiopharmaceuticals for select

For more information:

Visit our web site  or contact:

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201

Jeff Ramson
ProActive Capital Group, LLC
Tel: (646) 863-6341

Dennis S. Dobson Jr., 203-258-0159
Tel: (203) 258-0150

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance.
No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.